Home›Clinical trials›Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Not yet recruiting · NCT06737042

A study testing whether a new weekly shot from Gan and Lee Pharmaceuticals, USA, tirzepatide, can help with weight.

What this means for you

Who can join
Adults 18 to 75, have obesity or are overweight, BMI 27+.
What you take
tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The study runs about 16 months.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 2Sponsor Gan and Lee Pharmaceuticals, USADrug tirzepatideClass GLP-1/GIPSites 20 USEnrollment target 285

What this study is for

Primary condition: Obesity and Overweight.

Full scientific study title: Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants.

Who can join

Age18 to 75SexAnyBMI27 or higher

Adults 18 to 75, have obesity or are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • 18 to 75 years of age (both inclusive) at the time of signing the informed consent form (ICF).
  • History of failing to lose sufficient weight with lifestyle/dietary modification.
  • Hypertension: defined as taking blood pressure (BP) lowering medication or have a systolic blood pressure (SBP) of >=130 mmHg or a diastolic blood pressure (DBP) of >=80 mmHg at screening.
  • Dyslipidemia: defined as taking lipid-lowering medication or have LDL >=160 mg/dL (4.1 mmol/L) or triglycerides >=150 mg/dL (1.7 mmol/L), or high-density lipoprotein (HDL) <40 mg/dL (1.0 mmol/L) for men or HDL <50 mg/dL (1.3 mmol/L) for women at screening.
  • Obstructive sleep apnea.

Where this study is enrolling

This trial has 20 sites across 9 states. Contact a site coordinator directly to start screening.

Alabama2 sites
  • KUR Research - Trinity @ Bessemer, AL Site Network
    Bessemer, Alabama
    Cindy Thome205-225-7455cthome@kurr.com
  • KUR Research - Trinity @ Centreville Site Network
    Centreville, Alabama
    Brianna White205-225-7455bwhite@kurr.com
Arkansas2 sites
California4 sites
Florida4 sites
Maryland1 site
Massachusetts1 site
Nevada1 site
Ohio2 sites
Texas3 sites

Timeline

Started enrolling: 2025-02-12. Expected completion: 2026-06-22. Last updated on ClinicalTrials.gov: 2025-02-04.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.